NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
37 trialsNCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01652196 2025-02-05
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02384759 2024-07-10
FOLFA
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00407654 2024-03-04
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03530267 2024-02-23
ELDERLY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT01782443 2023-08-14
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03279289 2023-04-13
AFEMA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT03043729 2023-02-06
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
AIO-Studien-gGmbH
Phase 2 Completed
NCT02181556 2021-06-07
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02340949 2021-05-03
RIA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT02101918 2020-03-23
Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01669720 2020-02-17
C261
Brown University
Phase 2 Terminated
NCT01747551 2020-02-10
FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02331927 2019-09-20
PERMAD
University of Ulm
Phase 2 Unknown
NCT00462826 2019-07-23
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01258855 2019-05-10
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02624726 2019-02-22
MINOAS
Hellenic Oncology Research Group
Phase 2 Unknown
NCT00450255 2018-05-24
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02129257 2017-10-24
AMALTHEA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT03264274 2017-08-31
AUSCOR
Barts & The London NHS Trust
Phase 2 Withdrawn
NCT00828139 2017-08-21
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02079220 2017-07-31
A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT00357760 2017-06-23
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01882868 2017-03-14
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Phase 2 Completed
NCT01749956 2017-02-07
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02045030 2016-11-16
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer
CR-CSSS Champlain-Charles-Le Moyne
Phase 2 Terminated
NCT00390234 2015-12-07
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02235324 2015-05-06
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
University of Southern California
Phase 2 Withdrawn
NCT00509249 2015-01-08
Aflibercept in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01889680 2014-12-02
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer
NSABP Foundation Inc
Phase 2 Withdrawn
NCT02085005 2014-11-18
Drop and Go
Sanofi
Phase 2 Withdrawn
NCT00407485 2014-10-20
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Completed
NCT00601991 2013-04-02
A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT00396591 2013-01-10
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2 Completed
NCT00284141 2012-12-10
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Sanofi
Phase 2 Completed